Have to have contributed to the latest episode of Tradeoffs podcast on the nomination of RFK Jr potential nomination as HHS Secretary. https://lnkd.in/dWxWzryR The prior episode acts as introduction to this one.
Minervax ApS
Bioteknologi
Copenhagen, Capital Region 2.131 følgere
Developing a maternal vaccine for Group B Streptococcus
Om os
MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability. Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
- Websted
-
http://www.minervax.com
Eksternt link til Minervax ApS
- Branche
- Bioteknologi
- Virksomhedsstørrelse
- 2-10 medarbejdere
- Hovedkvarter
- Copenhagen, Capital Region
- Type
- Privat
- Specialer
- Group B Streptococcal og GBS
Beliggenheder
-
Primær
Se ruten
Ole Maaløes Vej 3
Copenhagen, Capital Region 2200, DK
Medarbejdere hos Minervax ApS
-
Anders Fink V.
CFO | M&A | IPO | Board | Strategy | Growth | Leadership | Financing
-
Søren Reffstrup Hansen
Experienced Business Controller with flair for numbers
-
Sten Verland, PhD MSc
Advisor and Non-Executive Director to Life Science Companies
-
Eileen Smits
Vice President Regulatory Affairs at MinervaX